A study questioned the use of brain volume loss as a clinical trial endpoint in PPMS after finding a weak link to disability ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on multiple sclerosis, has published groundbreaking new research ...

Clinicians and researchers have suspected for years that an aggressive, less-common form of multiple sclerosis (MS) is likely a distinct form of the disease. Now, new research conducted using a more ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...